Surfactant for the Treatment of ARDS in a Patient With COVID-19
Copyright © 2021 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved..
Patients with COVID-19 report severe respiratory symptoms consistent with ARDS. The clinical presentation of ARDS in COVID-19 is often atypical, as patients with COVID-19 exhibit a disproportionate hypoxemia compared with relatively preserved lung mechanics. This pattern is more similar to neonatal respiratory distress syndrome secondary to surfactant deficiency, which has been shown to benefit from exogenous surfactant. We present our experience with exogenous surfactant treatment in a patient with COVID-19 experiencing COVID-19-related ARDS. The patient responded with improved oxygenation, and we believe surfactant was the catalyst for the successful extubation and clinical improvement of the patient.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:160 |
|---|---|
| Enthalten in: |
Chest - 160(2021), 1 vom: 30. Juli, Seite e9-e12 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Heching, Moshe [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ARDS |
|---|
| Anmerkungen: |
Date Completed 20.07.2021 Date Revised 08.05.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.chest.2021.01.028 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM320554856 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM320554856 | ||
| 003 | DE-627 | ||
| 005 | 20231225173830.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.chest.2021.01.028 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1068.xml |
| 035 | |a (DE-627)NLM320554856 | ||
| 035 | |a (NLM)33493441 | ||
| 035 | |a (PII)S0012-3692(21)00100-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Heching, Moshe |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Surfactant for the Treatment of ARDS in a Patient With COVID-19 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.07.2021 | ||
| 500 | |a Date Revised 08.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Patients with COVID-19 report severe respiratory symptoms consistent with ARDS. The clinical presentation of ARDS in COVID-19 is often atypical, as patients with COVID-19 exhibit a disproportionate hypoxemia compared with relatively preserved lung mechanics. This pattern is more similar to neonatal respiratory distress syndrome secondary to surfactant deficiency, which has been shown to benefit from exogenous surfactant. We present our experience with exogenous surfactant treatment in a patient with COVID-19 experiencing COVID-19-related ARDS. The patient responded with improved oxygenation, and we believe surfactant was the catalyst for the successful extubation and clinical improvement of the patient | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a ARDS | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a surfactant | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Biological Products |2 NLM | |
| 650 | 7 | |a Pulmonary Surfactants |2 NLM | |
| 650 | 7 | |a calfactant |2 NLM | |
| 650 | 7 | |a Q4K217VGA9 |2 NLM | |
| 700 | 1 | |a Lev, Shaul |e verfasserin |4 aut | |
| 700 | 1 | |a Shitenberg, Dorit |e verfasserin |4 aut | |
| 700 | 1 | |a Dicker, Dror |e verfasserin |4 aut | |
| 700 | 1 | |a Kramer, Mordechai R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Chest |d 1970 |g 160(2021), 1 vom: 30. Juli, Seite e9-e12 |w (DE-627)NLM000002720 |x 1931-3543 |7 nnns |
| 773 | 1 | 8 | |g volume:160 |g year:2021 |g number:1 |g day:30 |g month:07 |g pages:e9-e12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.chest.2021.01.028 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 160 |j 2021 |e 1 |b 30 |c 07 |h e9-e12 | ||